Page 937 - Williams Hematology ( PDFDrive )

912 Part VI: The Erythrocyte Chapter 58: The Porphyrias 913

183. Grandchamp B: Acute intermittent porphyria. Semin Liver Dis 18(1):17, 1998. 217. Bloomer JR, Berk PD, Bonkowsky HL, et al: Blood volume and bilirubin production in
184. Kauppinen R, von und zu Fraunberg M: Molecular and biochemical studies of acute acute intermittent porphyria. N Engl J Med 284:17, 1971.
intermittent porphyria in 196 patients and their families. Clin Chem 48(11):1891, 2002. 218. Eales L, Dowdle EB, Sweeney GD: The acute porphyric attack. I. The electrolyte disor-
185. Wetterberg L: A Neuropsychiatric and Genetical Investigation of Acute Intermittent Por- der of the acute porphyric attack and the possible role of delta-aminolevulinic acid. S
phyria. Scandinavian University Books, Stockholm, 1967. Afr Med J Sep 25:89, 1971.
186. Mustajoki P, Kauppinen R, Lannfelt L, et al: Frequency of low erythrocyte porphobi- 219. Tschudy DP, Valsamis M, Magnussen CR: Acute intermittent porphyria: Clinical and
linogen deaminase activity in Finland. J Intern Med 231(4):389, 1992. selected research aspects. Ann Intern Med 83(6):851, 1975.
187. Nordmann Y, Puy H, Da Silva V, et al: Acute intermittent porphyria: Prevalence of 220. Andersson C, Wikberg A, Stegmayr B, et al: Renal symptomatology in patients with
mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern acute intermittent porphyria. A population-based study. J Intern Med 248(4):319,
Med 242(3):213, 1997. 2000.
188. Grandchamp B, Picat C, de Rooij F, et al: A point mutation G—A in exon 12 of the 221. Church SE, McColl KE, Moore MR, et al: Hypertension and renal impairment as com-
porphobilinogen deaminase gene results in exon skipping and is responsible for acute plications of acute porphyria. Nephrol Dial Transplant 7(10):986, 1992.
intermittent porphyria. Nucleic Acids Res 17(16):6637, 1989. 222. Barone GW, Gurley BJ, Anderson KE, et al: The tolerability of newer immunosup-
189. Anderson KE, Freddara U, Kappas A: Induction of hepatic cytochrome P-450 by nat- pressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol
ural steroids: Relationships to the induction of delta-aminolevulinate synthase and 41(1):113, 2001.
porphyrin accumulation in the avian embryo. Arch Biochem Biophys 217:597, 1982. 223. Nunez DJ, Williams PF, Herrick AL, et al: Renal transplantation for chronic renal fail-
190. Soonawalla ZF, Orug T, Badminton MN, et al: Liver transplantation as a cure for acute ure in acute porphyria. Nephrol Dial Transplant 2:271, 1987.
intermittent porphyria. Lancet 363(9410):705, 2004. 224. Ostrowski J, Kostrzewska E, Michalak T, et al: Abnormalities in liver function and
191. Kauppinen R, Mustajoki P: Prognosis of acute porphyria: Occurrence of acute attacks, morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias.
precipitating factors, and associated diseases. Medicine (Baltimore) 71(1):1, 1992. Gastroenterology 85:1131, 1983.
192. Kuo HC, Huang CC, Chu CC, et al: Neurological complications of acute intermittent 225. Hollander CS, Scott RL, Tschudy DP, et al: Increased protein bound iodine and thyrox-
porphyria. Eur Neurol 66(5):247, 2011. ine binding globulin in acute intermittent porphyria. N Engl J Med 277:995, 1967.
193. Lithner F: Could attacks of abdominal pain in cases of acute intermittent porphyria be 226. Mustajoki P, Nikkila EA: Serum lipoproteins in asymptomatic acute porphyria: No
due to intestinal angina? J Intern Med 247(3):407, 2000. evidence for hyperbetalipoproteinemia. Metabolism 33:266, 1984.
194. Anderson KE, Drummond GS, Freddara U, et al: Porphyrogenic effects and induction 227. Deacon AC, Peters TJ: Identification of acute porphyria: Evaluation of a commercial
of heme oxygenase in vivo by delta-aminolevulinic acid. Biochim Biophys Acta 676:289, screening test for urinary porphobilinogen. Ann Clin Biochem 35(Pt 6):726, 1998.
1981. 228. Minder EI: Coproporphyrin isomers in acute-Intermittent porphyria. Scand J Clin Lab
195. Brennan MJW, Cantrill RC: Delta-aminolaevulinic acid is a potent agonist for GABA Invest 53:87, 1993.
autoreceptors. Nature 280:514, 1979. 229. Blum M, Koehl C, Abecassis J: Variations in erythrocyte uroporphyrinogen I synthe-
196. Müller WE, Snyder SH: Delta-aminolevulinic acid: Influences on synaptic GABA tase activity in non porphyrias. Clin Chim Acta 87:119, 1978.
receptor binding may explain CNS symptoms of porphyria. Ann Neurol 2:340, 230. Kostrzewska E, Gregor A: Increased activity of porphobilinogen deaminase in erythro-
1977. cytes during attacks of acute intermittent porphyria. Ann Clin Res 18:195, 1986.
197. Meyer UA, Schuurmans MM, Lindberg RLP: Acute porphyrias: Pathogenesis of neu- 231. Bonkowsky HL, Tschudy DP: Hazard of propranolol in treatment of acute porphyria
rological manifestations. Semin Liver Dis 18(1):43, 1998. [letter]. Br Med J 4:47, 1974.
198. Jover R, Hoffmann F, Scheffler-Koch V, et al: Limited heme synthesis in porphobi- 232. Bonkowsky HL, Sinclair PR, Emery S, et al: Seizure management in acute hepatic por-
linogen deaminase-deficient mice impairs transcriptional activation of specific cyto- phyria: Risks of valproate and clonazepam. Neurology 30(6):588, 1980.
chrome P450 genes by phenobarbital. Eur J Biochem 267(24):7128, 2000. 233. Larson AW, Wasserstrom WR, Felsher BF, et al: Posttraumatic epilepsy and acute inter-
199. Lindberg RL, Martini R, Baumgartner M, et al: Motor neuropathy in porphobilinogen mittent porphyria: Effects of phenytoin, carbamazepine, and clonazepam. Neurology
deaminase-deficient mice imitates the peripheral neuropathy of human acute porphy- 28:824, 1978.
ria. J Clin Invest 103(8):1127, 1999. 234. Harper P, Wahlin S: Treatment options in acute porphyria, porphyria cutanea tarda,
200. Louis CA, Sinclair JF, Wood SG, et al: Synergistic induction of cytochrome-P450 by and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 10(6):444, 2007.
ethanol and isopentanol in cultures of chick embryo and rat hepatocytes. Toxicol Appl 235. Mustajoki P, Nordmann Y: Early administration of heme arginate for acute porphyric
Pharmacol 118:169, 1993. attacks. Arch Intern Med 153(17):2004, 1993.
201. Lip GY, McColl KE, Goldberg A, Moore MR: Smoking and recurrent attacks of acute 236. Tenhunen R, Mustajoki P: Acute porphyria: Treatment with heme. Semin Liver Dis
intermittent porphyria. Br Med J 302:507, 1991. 18(1):53, 1998.
202. Andersson C, Bylesjo I, Lithner F: Effects of diabetes mellitus on patients with acute 237. Jones RL: Hematin-derived anticoagulant. Generation in vitro and in vivo. J Exp Med
intermittent porphyria. J Intern Med 245(2):193, 1999. 163:724, 1986.
203. Kauppinen R: Prognosis of Acute Porphyrias and Molecular Genetics of Acute Intermit- 238. Bonkovsky HL, Healey JF, Lourie AN, et al: Intravenous heme-albumin in acute inter-
tent Porphyria in Finland [thesis]. University of Helskinki, Helsinki, 1992. mittent porphyria: Evidence for repletion of hepatic hemoproteins and regulatory
204. Milo R, Neuman M, Klein C, et al: Acute intermittent porphyria in pregnancy. Obstet heme pools. Am J Gastroenterol 86(8):1050, 1991.
Gynecol 73(3 Pt 2):450, 1989. 239. Anderson KE, Bonkovsky HL, Bloomer JR, et al: Reconstitution of hematin for intra-
205. Shenhav S, Gemer O, Sassoon E, et al: Acute intermittent porphyria precipitated by venous infusion. Ann Intern Med 144(7):537, 2006.
hyperemesis and metoclopramide treatment in pregnancy. Acta Obstet Gynecol Scand 240. Daimon M, Susa S, Igarashi M, et al: Administration of heme arginate, but not hema-
76(5):484, 1997. tin, caused anaphylactic shock. Am J Med 110(3):240., 2001.
206. Welland FH, Hellman ES, Gaddis EM, et al: Factors affecting the excretion of por- 241. Khanderia U: Circulatory collapse associated with hemin therapy for acute intermit-
phyrin precursors by patients with acute intermittent porphyria. I. The effect of diet. tent porphyria. Clin Pharm 5(8):690, 1986.
Metabolism 13:232, 1964. 242. Jeelani Dhar G, Bossenmaier I, Cardinal R, et al: Transitory renal failure following
207. Thaler MM, Dawber NH: Stimulation of bilirubin formation in liver of newborn rats rapid administration of a relatively large amount of hematin in a patient with acute
by fasting and glucagon. Gastroenterology 72(2):312, 1977. intermittent porphyria in clinical remission. Acta Med Scand 203:437, 1978.
207a. Anderson KE, Bloomer JR, Bonkovsky HL, et al: Recommendations for the diagnosis 243. Herrick AL, McColl KE, Moore MR, et al: Controlled trial of haem arginate in acute
and treatment of the acute porphyrias. Ann Intern Med 142:439, 2005 hepatic porphyria. Lancet 1(8650):1295, 1989.
208. Bernstein HD, Rapport TA, Walter P: Cytosolic protein translocation factors. Is SRP 243a. Anderson KE, Bloomer JR, Bonkovsky HL, et al: Recommendations for the diagnosis
Still unique? Cell 58:1017, 1989. and treatment of the acute porphyrias. Ann Intern Med 142:439, 2005.
209. Picat C, Delfau MH, De Rooij FWM, et al: Identification of the mutations in the par- 244. Cherem JH, Malagon J, Nellen H: Cimetidine and acute intermittent porphyria. Ann
ents of a patient with a putative compound heterozygosity for acute intermittent por- Intern Med 143(9):694, 2005.
phyria. J Inherit Metab Dis 13:684, 1990. 245. Horie Y, Tanaka K, Okano J, et al: Cimetidine in the treatment of porphyria cutanea
210. Bonkovsky HL, Maddukuri VC, Yazici C, et al: Acute porphyrias in the USA: Features tarda. Intern Med 35(9):717, 1996.
of 108 subjects from Porphyrias Consortium. Am J Med 127(12):1233, 2014. 246. Marcus DL, Nadel H, Lew G, et al: Cimetidine suppresses chemically induced experi-
211. Stein JA, Tschudy DP: Acute intermittent porphyria. A clinical and biochemical study mental hepatic porphyria. Am J Med Sci 300:214, 1990.
of 46 patients. Medicine (Baltimore) 49(1):1, 1970. 247. Anderson KE, Spitz IM, Bardin CW, et al: A GnRH analogue prevents cyclical attacks
212. Barohn RJ, Sanchez JE, Anderson KE: Acute peripheral neuropathy due to hereditary of porphyria. Arch Intern Med 150:1469, 1990.
coproporphyria. Muscle Nerve 17:793, 1994. 248. Yamamori I, Asai M, Tanaka F, et al: Prevention of premenstrual exacerbation of
213. Greenspan GH, Block AJ: Respiratory insufficiency associated with acute intermittent hereditary coproporphyria by gonadotropin-releasing hormone analogue. Intern Med
porphyria. South Med J 74(8):954, 959, 1981. 38(4):365, 1999.
214. Ridley A: Porphyric neuropathy, in Peripheral neuropathy, edited by Dyck PJ, Thomas 249. Anderson KE, Egger NG, Goeger DE: Heme arginate for prevention of acute porphyric
PK, Lambert EH, Bunge R, p 1704. WB Saunders, Philadelphia, 1984. attacks [abstract]. Acta Haematol 98(Suppl 1):120, 1997.
215. Stein JA, Curl FD, Valsamis M, et al: Abnormal iron and water metabolism in acute 250. With TK: Hereditary coproporphyria and variegate porphyria in Denmark. Dan Med
intermittent porphyria with new morphologic findings. Am J Med 53:784, 1972. Bull 30(2):106, 1983.
216. Goldberg A: Acute intermittent porphyria. A study of 50 cases. Q J Med 28:183, 251. Mustajoki P: Variegate porphyria. Twelve years’ experience in Finland. Q J Med
1959. 49(194):191, 1980.

Kaushansky_chapter 58_p0889-0914.indd 912 9/18/15 5:58 PM